Artelo Biosciences (NASDAQ:ARTL – Get Free Report) issued its quarterly earnings data on Wednesday. The company reported ($0.89) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by ($0.17), FiscalAI reports.
Artelo Biosciences Stock Down 1.6%
NASDAQ:ARTL traded down $0.01 during trading hours on Wednesday, reaching $0.73. 84,405 shares of the company’s stock were exchanged, compared to its average volume of 1,856,826. The company has a market capitalization of $1.71 million, a P/E ratio of -0.02 and a beta of -0.07. Artelo Biosciences has a 12 month low of $0.71 and a 12 month high of $31.65. The business’s 50-day simple moving average is $1.09 and its two-hundred day simple moving average is $3.11.
Wall Street Analyst Weigh In
A number of analysts have recently commented on ARTL shares. Wall Street Zen raised Artelo Biosciences from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 16th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Artelo Biosciences in a research note on Wednesday, June 24th. Two equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Reduce” and an average price target of $54.00.
Artelo Biosciences Company Profile
Artelo Biosciences, Inc is a clinical-stage biopharmaceutical company focused on the development of novel small-molecule therapies for pain, inflammation, ocular and cardiometabolic disorders. The company leverages a proprietary drug delivery and targeting platform designed to enhance the safety and efficacy profiles of well-characterized active pharmaceutical ingredients. Artelo’s approach is centered on repurposing and optimizing therapeutic molecules to address significant unmet medical needs, with particular emphasis on improving patient tolerability and clinical outcomes.
The company’s lead program, AB101, is an orally bioavailable ion channel modulator in development for neuropathic pain conditions including post-herpetic neuralgia.
Featured Stories
- Five stocks we like better than Artelo Biosciences
- GE Vernova’s AI Power Boom Faces a Profit Test
- Cardinal Health Earnings: Can Perfection Get Priced In Twice?
- Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not Demand
- Legacy Jet Builders Stall While Embraer Accelerates to New Highs
Receive News & Ratings for Artelo Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artelo Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
